RCC Real-World Data: Prognostic Factors and Risk Stratification in the Immunotherapy Era.

Sagie, Shira; Sarfaty, Michal; Levartovsky, Meital; Gantz Sorotsky, Hadas; Berger, Raanan; Percik, Ruth; Gadot, Moran

Sagie, Shira; Sarfaty, Michal; Levartovsky, Meital; Gantz Sorotsky, Hadas; Berger, Raanan; Percik, Ruth; Gadot, Moran.

Afiliación

Sagie S; Institute of Oncology, Sheba Medical Center, Ramat Gan 52621, Israel.
Sarfaty M; Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv 6997801, Israel.
Levartovsky M; The Sheba Talpiot Medical Leadership Program, Sheba Medical Center, Ramat Gan 52621, Israel.
Gantz Sorotsky H; Institute of Oncology, Sheba Medical Center, Ramat Gan 52621, Israel.
Berger R; Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv 6997801, Israel.
Percik R; Institute of Oncology, Sheba Medical Center, Ramat Gan 52621, Israel.
Gadot M; Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv 6997801, Israel.

Cancers (Basel) ; 14(13)2022 Jun 26.

Article en En | MEDLINE | ID: mdl-35804899

Palabras clave

checkpoint inhibitors; renal cell carcinoma; risk prognostication

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Tipo de estudio: Etiology_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Idioma: En Revista: Cancers (Basel) Año: 2022 Tipo del documento: Article País de afiliación: Israel

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google